Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | GALR1 | P47211 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.34 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.34 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13492162 | 0.94 | ALOX5 (0.49) | PIM1PIM2KDM4EALOX5NOTUM | |
| SCHEMBL3225879 | 0.79 | STK17B (0.45) | PIM1PIM2ALOX5LMNA | |
| SCHEMBL30692647 | 0.77 | KIT (0.53) | ALOX5ALDH1A1LMNASMN1; SMN2ACHE | |
| SCHEMBL4797164 | 0.72 | PLCG2 (0.47) | KDM4EALOX5NOTUMALDH1A1LMNA | |
| SCHEMBL3214270 | 0.72 | PLCG2 (0.47) | KDM4EALOX5NOTUMALDH1A1LMNA | |
| SCHEMBL2164776 | 0.72 | KDM4E (0.49) | KDM4EL3MBTL1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2164768 | 0.72 | KDM4E (0.49) | KDM4EL3MBTL1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2164772 | 0.72 | KDM4E (0.49) | KDM4EL3MBTL1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2650488 | 0.71 | ALDH1A1 (0.56) | KDM4EALOX5NOTUMALDH1A1CSNK2A1 | |
| SCHEMBL30692645 | 0.71 | AURKA (0.57) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586618-B2 | Furanone compounds and lactam analogues thereof | BIOSIGNAL LIMITED (AU) | 2013-11-19 | — | — | US | disclosed |
| US-8586618-B2 | Furanone compounds and lactam analogues thereof | BIOSIGNAL LIMITED (AU) | 2013-11-19 | — | — | US | disclosed |
| US-20100035948-A1 | Furanone compounds and lactam analogues thereof | UNILEVER PLC (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035948-A1 | Furanone compounds and lactam analogues thereof | UNILEVER PLC (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035948-A1 | Furanone compounds and lactam analogues thereof | UNILEVER PLC (GB) | 2010-02-11 | — | — | US | disclosed |
| WO-2008040097-A1 | FURANONE COMPOUNDS AND LACTAM ANALOGUES THEREOF | BIOSIGNAL LIMITED (AU) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040097-A1 | FURANONE COMPOUNDS AND LACTAM ANALOGUES THEREOF | BIOSIGNAL LIMITED (AU) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035948-A1 | Furanone compounds and lactam analogues thereof | FDPS, CYP2C19, MRPL21 | PIM1 2252/4885PIM2 1867/4885KDM4E 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.